Quercetin Derivatives as Potential Therapeutic Agents: An Updated Perspective on the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer

Int J Mol Sci. 2023 Oct 15;24(20):15208. doi: 10.3390/ijms242015208.

Abstract

Flavonoids are the largest group of polyphenols, represented by many compounds that exhibit high anticancer properties. Quercetin (Q) and its main derivatives (rutin, quercitrin, isoquercitrin, isorhamnetin, tamarixetin, rhamnetin, and hyperoside) in the class of flavonols have been documented to exert anticancer activity. Q has been shown to be useful in the treatment of non-small cell lung cancer (NSCLC), as demonstrated by in vitro/in vivo studies, due to its antitumor, anti-inflammatory, anti-proliferative, anti-angiogenesis, and apoptotic properties. Some flavonoids (flavone, anthocyanins, and proanthocyanidins) have been demonstrated to be effective in nicotine-induced NSCLC treatment. However, the molecular mechanisms of quercetin derivatives (QDs) in nicotine-induced NSCLC treatment remain unclear. Thus, this review aims to summarize the available literature on the therapeutic effects of QDs in nicotine-induced NSCLC.

Keywords: flavonoids; flavonols; molecular mechanisms; nicotine; non-small cell lung cancer; quercetin derivatives.

Publication types

  • Review

MeSH terms

  • Anthocyanins / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Flavonoids / pharmacology
  • Humans
  • Lung Neoplasms* / drug therapy
  • Nicotine / pharmacology
  • Nicotine / therapeutic use
  • Quercetin / pharmacology
  • Quercetin / therapeutic use

Substances

  • Quercetin
  • Nicotine
  • Anthocyanins
  • Flavonoids

Grants and funding

This research received no external funding.